Literature DB >> 24025583

The thyroid cancer PAX8-PPARG fusion protein activates Wnt/TCF-responsive cells that have a transformed phenotype.

Dang Vu-Phan1, Vladimir Grachtchouk, Jingcheng Yu, Lesley A Colby, Max S Wicha, Ronald J Koenig.   

Abstract

A chromosomal translocation results in the production of a paired box 8-peroxisome proliferator-activated receptor gamma (PAX8-PPARG) fusion protein (PPFP) in ∼35% of follicular thyroid carcinomas. To examine the role of PPFP in thyroid oncogenesis, the fusion protein was stably expressed in the non-transformed rat thyroid cell line PCCL3. PPFP conferred on PCCL3 cells the ability to invade through Matrigel and to form colonies in anchorage-independent conditions. PPFP also increased the fraction of cells with Wnt/TCF-responsive green fluorescent protein reporter gene expression. This Wnt/TCF-activated population was enriched for colony-forming and invading cells. These actions of PPFP required a functional PPARG DNA binding domain (DBD) within PPFP and were further stimulated by PPARG agonists. These data indicate that PPFP, through its PPARG DBD, induces Wnt/TCF pathway activation in a subpopulation of cells, and these cells have properties of cellular transformation including increased invasiveness and anchorage-independent growth.

Entities:  

Keywords:  PPFP; TCF; Wnt; thyroid carcinoma

Mesh:

Substances:

Year:  2013        PMID: 24025583      PMCID: PMC3839064          DOI: 10.1530/ERC-13-0058

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  51 in total

1.  The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition.

Authors:  J Gregory Powell; Xiying Wang; Brandon L Allard; Mustafa Sahin; Xiao-Li Wang; Ian D Hay; Henry J Hiddinga; Seema S Deshpande; Todd G Kroll; Stefan K G Grebe; Norman L Eberhardt; Bryan McIver
Journal:  Oncogene       Date:  2004-04-29       Impact factor: 9.867

2.  Beta-catenin dysregulation in thyroid neoplasms: down-regulation, aberrant nuclear expression, and CTNNB1 exon 3 mutations are markers for aggressive tumor phenotypes and poor prognosis.

Authors:  G Garcia-Rostan; R L Camp; A Herrero; M L Carcangiu; D L Rimm; G Tallini
Journal:  Am J Pathol       Date:  2001-03       Impact factor: 4.307

3.  A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity.

Authors:  S Rocchi; F Picard; J Vamecq; L Gelman; N Potier; D Zeyer; L Dubuquoy; P Bac; M F Champy; K D Plunket; L M Leesnitzer; S G Blanchard; P Desreumaux; D Moras; J P Renaud; J Auwerx
Journal:  Mol Cell       Date:  2001-10       Impact factor: 17.970

4.  A c-erb-A binding site in rat growth hormone gene mediates trans-activation by thyroid hormone.

Authors:  C K Glass; R Franco; C Weinberger; V R Albert; R M Evans; M G Rosenfeld
Journal:  Nature       Date:  1987 Oct 22-28       Impact factor: 49.962

5.  Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.

Authors:  V Korinek; N Barker; P J Morin; D van Wichen; R de Weger; K W Kinzler; B Vogelstein; H Clevers
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

6.  Troglitazone, the peroxisome proliferator-activated receptor-gamma agonist, induces antiproliferation and redifferentiation in human thyroid cancer cell lines.

Authors:  Jin-Woo Park; Rasa Zarnegar; Hajime Kanauchi; Mariwil G Wong; William C Hyun; David G Ginzinger; Margaret Lobo; Philip Cotter; Quan-Yang Duh; Orlo H Clark
Journal:  Thyroid       Date:  2005-03       Impact factor: 6.568

7.  Activation of non-canonical Wnt/JNK pathway by Wnt3a is associated with differentiation fate determination of human bone marrow stromal (mesenchymal) stem cells.

Authors:  Weimin Qiu; Li Chen; Moustapha Kassem
Journal:  Biochem Biophys Res Commun       Date:  2011-08-22       Impact factor: 3.575

8.  Proteomic analysis of differentially expressed proteins in normal human thyroid cells transfected with PPFP.

Authors:  Xinying Li; Zhiming Wang; Jianming Liu; Cane Tang; Chaojun Duan; Cui Li
Journal:  Endocr Relat Cancer       Date:  2012-09-21       Impact factor: 5.678

9.  Plakoglobin is a new target gene of histone deacetylase in human fibrosarcoma HT1080 cells.

Authors:  Joong Sup Shim; Dong Hoon Kim; Ho Jeong Kwon
Journal:  Oncogene       Date:  2004-03-04       Impact factor: 9.867

10.  Depletion of epithelial stem-cell compartments in the small intestine of mice lacking Tcf-4.

Authors:  V Korinek; N Barker; P Moerer; E van Donselaar; G Huls; P J Peters; H Clevers
Journal:  Nat Genet       Date:  1998-08       Impact factor: 38.330

View more
  6 in total

1.  Adipogenic Differentiation of Thyroid Cancer Cells Through the Pax8-PPARγ Fusion Protein Is Regulated by Thyroid Transcription Factor 1 (TTF-1).

Authors:  Bin Xu; Michael O'Donnell; Jeffrey O'Donnell; Jingcheng Yu; Yanxiao Zhang; Maureen A Sartor; Ronald J Koenig
Journal:  J Biol Chem       Date:  2016-07-19       Impact factor: 5.157

Review 2.  Pax-8-PPAR-γ fusion protein in thyroid carcinoma.

Authors:  Priyadarshini Raman; Ronald J Koenig
Journal:  Nat Rev Endocrinol       Date:  2014-07-29       Impact factor: 43.330

Review 3.  Coding Molecular Determinants of Thyroid Cancer Development and Progression.

Authors:  Veronica Valvo; Carmelo Nucera
Journal:  Endocrinol Metab Clin North Am       Date:  2018-12-23       Impact factor: 4.741

4.  Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.

Authors:  Xuguang Zhu; Keisuke Enomoto; Li Zhao; Yuelin J Zhu; Mark C Willingham; Paul Meltzer; Jun Qi; Sheue-Yann Cheng
Journal:  Clin Cancer Res       Date:  2016-07-20       Impact factor: 12.531

Review 5.  Pathological bases for a robust application of cancer molecular classification.

Authors:  Salvador J Diaz-Cano
Journal:  Int J Mol Sci       Date:  2015-04-17       Impact factor: 5.923

6.  Genomic binding and regulation of gene expression by the thyroid carcinoma-associated PAX8-PPARG fusion protein.

Authors:  Yanxiao Zhang; Jingcheng Yu; Chee Lee; Bin Xu; Maureen A Sartor; Ronald J Koenig
Journal:  Oncotarget       Date:  2015-12-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.